Institutional investors and professional traders rely on The Fly to learn which companies the best analysts on Wall Street are saying to buy and sell.

Research analysts at Wall Street's largest banks issue recommendations on whether a stock should be bought, held, or sold. The Fly's team of financial market experts scours hundreds of research notes daily to uncover the best trading ideas. Check out today's top analyst calls from around Wall Street, compiled by The Fly.

Top 5 Upgrades:

• Mizuho analyst Gregg Moskowitz upgraded Fortinet (FTNT) to Buy from Neutral with a price target of $350, up from $340. The company reported "another very good upside quarter," led by bookings growth of 50% year-over-year and product revenue growth of 54%, Moskowitz told investors in a research note.
• Wells Fargo analyst Steven Cahall upgraded Sinclair Broadcast (SBGI) to Overweight from Equal Weight with a price target of $33, up from $30. The analyst noted that with the deconsolidation of Diamond, Sinclair's shares are no longer dragging the anchor of a highly levered regional sports narrative, and what re-emerges is a TV broadcast pureplay akin to peers.
• Guggenheim analyst Charles Zhu upgraded Zymeworks (ZYME) to Buy from Neutral with a $14 price target. While he remains cautious on the company's near-term data milestones at ASCO 2022, given his view that zanidatamab will likely read out a clinically-active profile that will have insufficient follow-up for cross-trial comparisons, Zhu believes shares are trading at a level reflective of investors' low expectations and his "conservative" odds-of-success-adjusted peak sales estimates for zanidatamab imply upside from current levels.
• Citi analyst Joanne Wuensch upgraded Nevro (NVRO) to Buy from Neutral with an unchanged price target of $78 post first quarter results. The impact of omicron faded throughout the quarter and the company's procedure funnel is beginning to build, Wuensch contended.
• OTR Global upgraded its view on Autodesk (ADSK) to Positive from Mixed following checks.

Top 5 Downgrades:

• Argus analyst Jim Kelleher downgraded Twitter (TWTR) to Hold from Buy. The analyst cited the approval by the company's board to be taken private by Elon Musk.
• Argus analyst David Toung downgraded Teladoc (TDOC) to Hold from Buy. The company is facing increased competition in the direct-to-consumer market for behavioral health services, and paying more to acquire new members, the analyst noted.
• Bank of America analyst Robert Ohmes double downgraded Sprouts Farmers Market (SFM) to Underperform from Buy with a price target of $25, down from $40. The company's new outlook calls for double digit percent cost inflation and price increases to continue for the balance of 2022 versus a previous expectation of easing inflation, Ohmes pointed out.
• Evercore ISI analyst David Palmer downgraded Brinker International (EAT) to In Line from Outperform with a price target of $40, down from $60. Even with a "solid" on-premise sales recovery and upcoming pricing, the analyst now sees restaurant margin for fiscal 2023 remaining below pre-COVID level and Brinker's stock as likely "dead money" in the near-term.
• Citi analyst Wendy Nicholson downgraded Tupperware Brands (TUP) to Neutral from Buy with a price target of $13, down from $26. Though the company has continued to make progress on many of its operational initiatives, its first quarter earnings underscore the difficulty that Tupperware is having in really turning its business around, Nicholson told investors in a research note. DA Davidson analyst Linda Bolton Weiser also downgraded Tupperware Brands to Neutral from Buy with a price target of $13, down from $32.

Top 5 Coverage Initiations:

• Barclays analyst Raimo Lenschow reinstated coverage of Skillsoft (SKIL) with an Overweight rating and $7 price target following the close of the Codecademy acquisition and fourth quarter results.
• Credit Suisse analyst Kaumil Gajrawala initiated coverage of Beachbody Company (BODY) with a Neutral rating and $2.27 price target. The analyst believes topline uncertainty, declining profitability, and limited flexibility owing to a tight liquidity position create a risk/reward setup that offers limited upside.
• Cantor Fitzgerald analyst Olivia Brayer assumed coverage of Aurinia Pharmaceuticals (AUPH) with an Overweight rating with a price target of $25, down from $34. Shares have had a difficult start to 2022, with COVID headwinds weighing on the company's first commercial launch, but Brayer thinks sentiment is at or near the bottom, and sees now as a time to re-position into the name.
• Barrington analyst James Goss initiated coverage of Cumulus Media (CMLS) with an Outperform rating and $21 price target. The company has a solid position in core spot radio, significant network radio operations enabling access to national advertising clients and growing digital exposure with podcasting of growing importance, Goss told investors in a research note.
• Benchmark analyst Cody Acree assumed coverage of Qorvo (QRVO) with a Buy rating with a price target of $152, down from $175, citing recent multiple compression across the group.